INM
Income statement / Annual
Last year (2024), InMed Pharmaceuticals Inc.'s total revenue was $4.60 M,
an increase of 11.18% from the previous year.
In 2024, InMed Pharmaceuticals Inc.'s net income was -$7.68 M.
See InMed Pharmaceuticals Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
| Operating Revenue |
$4.60 M
|
$4.14 M
|
$1.09 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$6.99 B |
$2.73 M |
$545,889.00 |
$197,031.00 |
$183,090.00 |
$93,940.00 |
$92,777.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$6.99 B |
$1.40 M |
$543,546.00 |
-$197,031.00 |
-$183,090.00 |
-$93,940.00 |
-$92,777.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
-1520.11 |
0.34 |
0.5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$3.77 B
|
$3.73 M
|
$7.28 M
|
$5.34 M
|
$5.20 M
|
$4.30 M
|
$1.52 M
|
$573,723.00
|
$292,840.00
|
$759,851.00
|
| General & Administrative
Expenses |
$5.25 B
|
$5.85 M
|
$6.87 M
|
$4.48 M
|
$3.50 M
|
$6.00 M
|
$0.00
|
$2.79 M
|
$1.48 M
|
$2.62 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$474,943.00
|
$706,229.00
|
$0.00
|
$844,275.00
|
$112,640.00
|
$498,436.00
|
| Selling, General &
Administrative Expenses |
$5.25 B
|
$5.85 M
|
$6.87 M
|
$4.48 M
|
$3.50 M
|
$6.00 M
|
$5.17 M
|
$2.79 M
|
$1.48 M
|
$2.62 M
|
| Other Expenses |
$0.00 |
-$308,940.00 |
$185,657.00 |
$120,866.00 |
$161,969.00 |
$94,716.00 |
-$0.00 |
$75,216.00 |
$67,408.00 |
$75,757.00 |
| Operating Expenses |
$9.02 B |
$9.78 M |
$14.34 M |
$9.94 M |
$8.87 M |
$10.39 M |
$6.69 M |
$3.44 M |
$1.84 M |
$3.46 M |
| Cost And Expenses |
$16.01 B |
$12.51 M |
$14.88 M |
$9.94 M |
$8.87 M |
$10.39 M |
$6.78 M |
$3.44 M |
$1.84 M |
$3.46 M |
| Interest Income |
$527,901.00 |
$492,440.00 |
$96,090.00 |
$16,017.00 |
$125,885.00 |
$330,441.00 |
$69,546.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$96,090.00 |
$360,350.00 |
$18,616.00 |
$0.00 |
$0.00 |
$495.17 |
$47.92 |
$3,525.31 |
| Depreciation &
Amortization |
$604,518.00
|
$595,997.00
|
$511,787.00
|
$197,031.00
|
$183,090.00
|
$94,716.00
|
$89,602.00
|
$75,216.00
|
$67,408.00
|
$75,757.00
|
| EBITDA |
-$7.06 M
|
-$10.83 M
|
-$17.26 M
|
-$9.80 M
|
-$8.58 M
|
-$10.26 M
|
-$6.69 M
|
-$3.36 M
|
-$1.77 M
|
-$3.38 M
|
| EBITDA Ratio |
-1.54 |
-1.87 |
-12.1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
-1977.13
|
-12.57
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$246.38 M
|
$588,531.00
|
-$1.10 M
|
$2.12 M
|
$60,733.00
|
$262,101.00
|
$69,774.00
|
-$495.17
|
-$47.92
|
-$3,525.31
|
| Income Before Tax |
-$7.67 M |
-$7.93 M |
-$18.60 M |
-$10.20 M |
-$8.68 M |
-$10.10 M |
-$6.71 M |
-$3.44 M |
-$1.84 M |
-$3.46 M |
| Income Before Tax Ratio
|
-1.67
|
-1.92
|
-17.07
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$7,100.00 |
$13,100.00 |
$4.81 M |
$360,350.00 |
$18,616.00 |
-$262,101.61 |
-$69,542.00 |
$495.17 |
$47.92 |
$3,525.31 |
| Net Income |
-$7.68 M |
-$7.95 M |
-$18.60 M |
-$10.20 M |
-$8.94 M |
-$10.01 M |
-$6.71 M |
-$3.44 M |
-$1.84 M |
-$3.46 M |
| Net Income Ratio |
-1.67 |
-1.92 |
-17.07 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.01 |
-3.25 |
-33.17 |
-37.78 |
-42.57 |
-47.67 |
-38.85 |
-31.73 |
-25.18 |
-61.89 |
| EPS Diluted |
-1.01 |
-3.25 |
-33.17 |
-37.78 |
-42.57 |
-47.67 |
-38.85 |
-31.73 |
-25.18 |
-61.89 |
| Weighted Average Shares
Out |
$7.59 M
|
$2.45 M
|
$560,751.00
|
$270,000.00
|
$210,000.00
|
$210,000.00
|
$172,668.00
|
$108,427.00
|
$72,966.00
|
$55,872.00
|
| Weighted Average Shares
Out Diluted |
$7.59 M
|
$2.45 M
|
$560,829.00
|
$270,000.00
|
$210,000.00
|
$210,000.00
|
$172,668.00
|
$108,427.00
|
$72,966.00
|
$55,872.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
